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Background: A wireless motility capsule is a new method for ambulatory assessment of transit times and motility
throughout the gastrointestinal tract. The objective of this study was to evaluate the ability of a wireless motility
capsule to detect drug effects on gastric emptying time (GET) and gastric contractility.
Methods: 15 healthy adults were administered in random order saline, erythromycin IV 150 mg, or morphine IV
0.05 mg/kg BW. Subjects ate a standard meal after each infusion, and subsequently ingested the motility capsule.
Data were recorded for 8 hours, and the results were analyzed using the manufacturer’s software.
Results: GET was significantly faster after erythromycin than either saline or morphine. Morphine tended to delay
emptying of the capsule compared to saline. There was a trend toward a greater frequency of gastric contractions with
erythromycin and a reduced frequency of gastric contractions with morphine that did not reach statistical significance.
Conclusions: A wireless motility capsule successfully detected acceleration of gastric emptying induced by
erythromycin, and retardation of gastric motility caused by morphine. These results indicate that a wireless motility
capsule is a promising technique to assess pharmacologic effects on gastric transit and contractility and aid in
development of drugs for gastric motor disorders.
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Disorders of gastric motility are commonly encountered
in clinical practice. Gastroparesis results from a variety
of neuropathic and myopathic disorders, most commonly
diabetes mellitus, post-gastric or esophageal surgery, or as
an idiopathic abnormality often following a viral infection
[1]. Delayed gastric emptying also occurs in some patients
with gastroesophageal reflux disease and functional dys-
pepsia [2]. Accelerated gastric emptying may result from
gastric surgery, causing the dumping syndrome, and also is
observed early in the course of diabetes [3,4]. Both delayed
and accelerated gastric motility can significantly interfere
with a patient’s quality of life. Upper gastrointestinal symp-
toms such as nausea, vomiting, and abdominal pain are
frequent side effects of many medications, and may be due* Correspondence: mdsitrin@buffalo.edu
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distribution, and reproduction in any mediumin part to drug effects on upper gastrointestinal tract tran-
sit and contractility. Evaluation of gastric motility is usually
performed by gastric scintigraphy or 13C-labeled acetate
and octanoic acid breath tests [5]. Gastric scintigraphy in-
volves a 12-hour fast and subsequent ingestion of a stan-
dardized meal labeled with a radioactive isotope. Imaging
of the radio-labeled meal tracks its course throughout the
upper gastrointestinal tract. Studies have shown that the
test should be conducted for 4 hours to optimize the abil-
ity to distinguish normal from delayed gastric emptying
[6]. The exposure of volunteer subjects to the radioactive
meal and the need for access to nuclear medicine facilities
for a prolonged time can be problematic for drug develop-
ment research. The accuracy of the 13C -labeled acetate
and octanoic acid breath tests is comparable to scintig-
raphy, however the use of these tests is also restricted by
limited availability and expense of mass spectrometry re-
sources. A method to safely assess upper gastrointestinal
tract motility in ambulatory subjects would be of signifi-
cant benefit in the development of new treatments fortral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gastrointestinal side effects of drugs in general.
In this study, we have tested the hypothesis that an am-
bulant wireless motility capsule (SmartPillR, SmartPillR
Corporation, Buffalo, NY) can detect changes in gastric
emptying and motor activity induced by moderate doses
of erythromycin and morphine.
Methods
Subjects
The subjects were 15 healthy adults, 12 males and 3 fe-
males ages 19 to 65. All subjects were evaluated with a
medical history, complete physical examination, electrocar-
diogram, complete blood count, comprehensive metabolic
panel, and thyroid stimulating hormone level prior to re-
ceiving any infusions. Pregnancy tests were performed in
females of child bearing potential prior to each infusion.
No smoking or alcohol use was allowed for at least 24
hours prior to each visit. Exclusion criteria included
chronic cardiovascular disease, chronic pulmonary dis-
ease, morbid obesity, sleep apnea, chronic gastrointes-
tinal or liver disease, history of gastrointestinal surgeries,
diabetes, hyperthyroidism, hypothyroidism, renal or urin-
ary tract disease, and pregnancy or lactation. Patients with
an allergy to any of the study medications or components
of the test meal and those taking medications which may
affect bowel motility (narcotics, anticholinergics, calcium
channel blockers) or gastric pH (proton pump inhibitors,
H2 receptor blockers) were also excluded.
Study protocol
The subjects were evaluated at the study center on three
different occasions separated by at least one week. In ran-
dom order, each subject was administered an intravenous
infusion of either 100 cc of saline (placebo), erythromycin
150 mg in saline, or morphine 0.05 mg/kg of body weight
in saline. Each infusion was given over a 20-minute period.
The doses of medication were selected to produce a mod-
erate effect on gastric emptying based on prior studies util-
izing other methods for studying gastrointestinal transit
[7,8]. Subjects were not aware of the infusion they received
on a given test day.
At the completion of the infusion, the subject ingested a
standardized meal consisting of a nutrient bar (SmartBarR)
that is composed of 66% carbohydrates, 17% protein, 2%
fat and 3% fiber. Subsequently, the subject ingested the ac-
tivated SmartPillR, which records pressure and pH data
and transmits it to a SmartPillR Data Receiver worn by the
patient. After capsule ingestion, the subjects were observed
in the study center for 8 hours, throughout which all data
were recorded. Six hours after capsule ingestion, each sub-
ject was allowed to drink 1 bottle of EnsureR nutritional
drink. Subjects either retrieved and returned the SmartPillR
capsule or had an abdominal x-ray in 1 week to documentcapsule passage from the body. The protocol was approved
by the University at Buffalo and VA Western New York
IRBs. Written informed consent for participation in the
study was obtained from the subjects.SmartPillR technology
The system includes a wireless motility capsule, data re-
ceiver, and data analysis software GIMS Data Viewer v.1.4
and SmartPill MotiliGI, which are provided by the manu-
facturer. The capsule size is 26 mm × 13 mm, similar to
the GivenR endoscopy capsule. The SmartPillR contains
sensors that measure pH, pressure, and temperature. pH
was measured every 5 seconds, and pH changes from 0.5
to 9.0 were detected with a sensitivity of ±0.5 pH units.
Pressure measurements from 0–350 mmHg were acquired
every 0.5 second, and temperatures from 25-49°C obtained
every 20 seconds. At the end of each 8-hour study period,
data were downloaded to a laptop computer for analysis.Data analysis
Gastric emptying time (GET) was defined as the time from
capsule ingestion to an abrupt and sustained rise in pH ≥ 2
units from the lowest postprandial value to ≥ 4, which indi-
cates that the capsule exited the acidic gastric antrum and
entered the alkaline duodenum. The frequency, area under
the pressure curve (AUC) and motility index of contrac-
tions during capsule residence in the stomach were evalu-
ated using both 10 mmHg and 20 mmHg above baseline
as the minimal contraction threshold. The motility index
was calculated as described by Camilleri et al.: MI = Ln
(sum of pressure amplitudes * number of contractions +1)
[9]. The analyses of the GETs and motility data were per-
formed by investigators who were not aware of the test in-
fusion conditions.Statistical analysis
GETs great than 6 hours, the time at which the nutri-
tional drink was given, were treated as censored in the
analysis, and estimates of mean and standard deviation
were based on an assumed normal-based model. Two-
sided exact sign tests which do not depend on the actual
GET values, but rather the relative ordering were used
to compare GETs between the three test infusions. In the
analysis of average gastric contractions a linear model was
utilized. The log transformation was first applied in order
to meet statistical assumptions. Once the model was fit,
specific linear contrasts based on the estimated model pa-
rameters were constructed and used to statistically com-
pare groups in a pairwise fashion. A nominal significance
level of 0.05 was used in all testing and all analyses were
carried out using SAS version 9.1.3 statistical software
(Cary, NC).
Table 1 Effects of erythromycin and morphine on mean
gastric emptying time
Drug Mean GET in hours ± SD
Erythromycin 2.07 (± 1.32)
Saline 3.38 (± 1.47)
Morphine 4.52 (± 1.55)
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All 15 subjects completed the entire study, and were eval-
uated under all three experimental conditions. The sub-
jects experienced no adverse events from the study drugs,
and were unable to tell whether they were receiving saline,
erythromycin, or morphine.Gastric emptying time
Table 1 shows the estimated mean GET in hours for each
study condition. In 6 of the 45 tests (2 saline, 1 erythro-
mycin, and 3 morphine), the capsule did not empty the
stomach within 6 hours, prior to ingestion of the liquid
formula meal. Although there were censored observations
present, the relative order of GETs for each subject under
the three test conditions was still identifiable. Differences
in GET between the conditions, therefore, were tested
via two-sided exact sign tests. After receiving erythro-
mycin, the subjects had a mean gastric emptying time of
2.07 hours, which was faster than the GET of 3.38 hours
after the saline infusion. In 13 of the 15 subjects, GET
was faster when the subject received erythromycin com-
pared to the saline placebo (p < 0.001, Figure 1). In con-
trast, mean GET after morphine administration was longerFigure 1 Individual subject gastric emptying times after administratio
more rapid after erythromycin than saline in 13 of 15 subjects, p < 0.001.than after saline, 4.52 hours versus 3.38 hours (Table 1). In
11 of the 15 subjects, GET was slower after the morphine
infusion than after saline (p = 0.11, Figure 2). The GET
after erythromycin was shorter than after morphine in 14
of 15 subjects (p <0.01), with a mean difference of almost 3
hours between the two medications (Table 1).
Contractility
The frequency of gastric contractions was assessed under
the three experimental conditions during the entire time
the motility capsule was in the stomach, up to a maximum
of 6 hours at which time the liquid nutritional formula was
ingested. Data were analyzed using both 10 mmHg and
20 mmHg above baseline as the minimum pressure thresh-
old for a contraction. With the 10 mmHg threshold there
was no significant effect of either erythromycin or mor-
phine on gastric contraction frequency (Table 2). Using the
20 mmHg threshold there was a trend for the frequency of
gastric contractions to be reduced with morphine com-
pared to either saline or erythromycin that did not reach
statistical significance (Table 2). Gastric contraction fre-
quency was lower with morphine than with either saline or
erythromycin in 10 of the 15 subjects. Gastric contraction
frequency after erythromycin administration was greater
than that seen with saline in 10 of the 15 subjects, but be-
cause of great variability in the contraction frequency ob-
served with erythromycin there was no statistical difference
in the mean values.
Using both a 10 mmHg and 20 mmHg contraction
threshold, neither erythromycin nor morphine had a sig-
nificant effect on area under the pressure curve or motil-
ity index.n of saline or erythromycin. Gastric emptying of the capsule was
Figure 2 Individual subject gastric emptying times after administration of saline or morphine. Gastric emptying of the capsule was slower
after morphine than saline in 11 of 15 subjects, p = 0.11.
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A wireless motility capsule is being increasingly used for
the assessment of transit time and motility throughout
the gastrointestinal tract. The capsule contains pH, tem-
perature, and pressure sensors that permit detection of
emptying of the capsule from the stomach into the duo-
denum, transition from the ileum to the right colon [10],
and exit from the body, as well as assessment of contrac-
tions in different segments of the gastrointestinal tract.
Previous studies have shown a good correlation between
gastric emptying of a radiolabeled meal and gastric resi-
dence time of the capsule [11]. Furthermore, significant
differences in gastric emptying time of the capsule were
observed between healthy controls and patients with a
history of gastroparesis [12]. The wireless motility capsule
also was capable of detecting differences in the frequency
and motility index of antral and duodenal contractions in
patients with severe gastroparesis compared to healthy
controls or patients with mild to moderate gastroparesis
[13]. A wireless motility capsule can also be used to assessTable 2 Mean number of contractions per minute during
the entire gastric residence of the capsule under
different experimental conditions
Drug Contraction frequency (SD)
(minimum contraction
threshold = 10 mmHg)
Contraction frequency (SD)
(minimum contraction
threshold = 20 mmHg)
Erythromycin 1.14 (± 1.02) 0.48 (± 0.58)
Saline 1.10 (± 0.74) 0.37 (± 0.26)
Morphine 0.94 (± 0.48) 0.29 (± 0.16)*
*p = 0.14 morphine vs erythromycin, p = 0.12 saline vs morphine.transit time through the whole gut, small intestine, and
large intestine, and whole gut and colonic transit times
have been shown to correlate well with conventional radio-
opaque markers [14]. Movement of the capsule through
the colon is delayed in patients with slow transit constipa-
tion as defined by radioopaque markers [14]. A wireless
motility capsule also correlates well with whole gut scintig-
raphy in the evaluation of whole gut transit time [15].
In the present study, we have tested the hypothesis
that a wireless motility capsule can measure drug effects
on gastrointestinal motility. In this proof of principle
study, we used agents that typically accelerate (erythro-
mycin) or slow (morphine) gastric emptying. We selected
doses of these agents that produced modest effects on gas-
tric emptying time that would be most relevant to drugs
in clinical practice or pharmaceutical development [7,8].
Administration of 150 mg of erythromycin which acts as a
motilin receptor agonist caused a mean decrease of cap-
sule emptying time of about 90 minutes compared to the
saline control, and gastric emptying was more rapid after
erythromycin than after saline administration in 13 of 15
subjects. In contrast, morphine resulted in delay of gastric
emptying time of more than one hour compared to saline.
The effect of morphine on gastric emptying time was
somewhat variable, with the capsule emptying being de-
layed by morphine administration in 11 of the 15 test sub-
jects. The variability may be explained, in part, by complex
effects of morphine on gastrointestinal motor function,
as opiates interfere with both stimulatory and inhibitory
neural pathways [16,17]. Although morphine usually delays
gastric emptying, previous studies found that narcotics
can cause phasic contractions, including some that mimic
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times result in emptying of the capsule from the stomach
[16,17].
Cassilly, et al. simultaneously used antroduodenal cath-
eter manometry, gastric emptying scintigraphy, and a wire-
less motility capsule to study gastric emptying and upper
gastrointestinal tract motility in normal volunteers [18].
They found that approximately 2/3 of patients emptied
the wireless motility capsule from the stomach with either
the first or second phase III migrating motor complex
(MMC); 1/3 of patients emptied it with isolated antral
contractions. Thus, differences in the type of contraction
that propelled the capsule on the three test days also likely
contributed to some of the variability in drug effects on
capsule emptying observed in this study. In prior studies
using the wireless motility capsule employed in this paper,
5–10 percent of healthy subjects with normal emptying of
a meal retained the capsule in the stomach for greater
than 6 hours [11-13]. This difference between emptying of
a meal and a solid inert object is a limitation of the use of
wireless capsule manometry.
In evaluating the ability of a wireless motility capsule
to detect pharmacologic effects on gastric contractility,
we found a numerical trend towards an increased num-
ber of contractions after administration of erythromycin
and a decreased frequency of gastric contractions with the
administration of morphine, particularly using 20 mmHg
above baseline as the contraction threshold. These effects,
however, were quite variable and not statistically signifi-
cant. Studies using antroduodenal manometry to assess the
effects of erythromycin and morphine on gastric contrac-
tions have also demonstrated complex dose-dependent ac-
tions [19-21]. Further studies of the role of a wireless
motility capsule in assessing the effects of drugs on gastric
contraction patterns will need a larger numbers of subjects,
more detailed analyses than simple measures of contrac-
tion frequency and amplitude, and evaluation of dose-
dependent responses.
None of our study patients suffered any adverse effects
as a result of this study, including prolonged capsule re-
tention. Data from studies of the device used for video
capsule endoscopy that is of similar size have shown that
it is a safe and well-tolerated procedure [22].
Conclusions
The results of this study indicate that a wireless motility
capsule may be a very useful tool for assessing actions of
drugs on upper gastrointestinal tract motility. Using a
modest number of subjects, we demonstrated that the
technique can measure drug effects on gastric emptying
time. Wireless capsule motility is performed on an am-
bulatory basis and avoids disadvantages inherent in gas-
tric scintigraphy, such as radiation exposure and a long
test period in a nuclear medicine facility which can beproblematic for research volunteers. 13C-labeled acetate-
and -octanoic acid breath tests are limited by the cost and
availability of mass spectrometry resources. Evaluation of
the effects of pharmacologic agents on gastric emptying
using a wireless motility capsule may be an important ini-
tial step in the development of new drugs for the treat-
ment of gastric motor disorders before embarking on
clinical trials requiring large numbers of subjects.
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